confid dd approv w/ attract risk/reward ndd
messag despit concern roxadustat futur pt pool safeti analysi reveal fgen messag
along azn feedback leav us high convict us approv dialysi depend dd patient
anemia forecast azn-book roxadustat sale base approv dd-relat anemia us/row
broad ckd-relat anemia approv china howev deep dive report suggest investor may write addl us
oppti non-dialysi depend ndd anemia soon maintain buy pt net
convict roxadustat us approv dialysi depend dd anemia treatment high non-dialysi
depend ndd patient pool materi upsid oppti view far dead base evalu believ
roxadustat dd-relat anemia indic like approv late estim roxadustat base case sale azn
addit ndd-ckd repres signific opportun uniqu valu proposit roxadustat
histor failur meet fda non-inferior bar cv safeti either overal mace composit affymax affi nc
takeda tak nc omonti compon amgn nc aranesp set high bar analysi
fgen commun togeth follow discuss azn ln buy suggest us investor reaction
admittedli confus commun set attract risk/reward oppti head full present data given view
dd us/row broad label china justifi current forecast data present hope
earli novemb point estim mace composit compon mi stroke death non-inferior
placebo establish mace exposure-adjust analysi believ investor confid rapidli improv
favor ndd approv
what known strongli support dd approv roxadustat pool mace/mac safeti result analog esa
suggest us approv bar clear admittedli tougher smaller market oppti roxadustat favor
dd follow esa studi includ omontyss emerald studi approv base comparison
mace safeti composit compon vs amgn epogen epoetin alpha upper bound ci hazard ratio
hr commun earn call dd point estim hr direct
consist mace compon composit follow discuss azn highlight high confid us
dd label roxadustat
view great unknown fda data full dataset ndd patient group present
investor confid unlik chang view roxa chanc ndd approv base studi
neg impact esa treat aranesp pearl omonti choir ndd patient either fail demonstr
non-inferior composit pearl choir importantli sole one compon mace like stroke treat
fgen/azn commun roxadustat pool mace safeti result ndd show clinic meaning differ vs
placebo impli compar placebo result like encompass signific outlier composit great
unknown remain us fda azn/fgen nc state fda consid total evid
ndd data fulli present firm guidanc fda non-inferior margin statist analysi plan
ndd investor confid ndd like remain mute despit see posit risk/reward
page analyst certif import disclosur
page analyst certif import disclosur
market epoetin alpha esa ww declin rate
compound-annual-growth-rate last decad
novel hif agent critic revers trend includ hif agent esa consensu forecast
anti-anemia market sale ww us
roxadustat lead oral hif-phi agent develop partnership w/ azn alpmi
approv dec china dialysi depend patient w/ launch expect
may perhap confus commun key data outcom patient
dataset wit year work biopharma roxadustat pool headlin safeti result
mace mace releas azn//astella subsequ discuss
manag result confer call
ambigu commun azn/fgen left investor perplex strong neg bia
perhap greatest sourc confus lack firm agreement fda non-
inferior margin mace contrast clear commun drug safeti base
ema establish non-inferior margin like upper bound confid interv
use better power mace endpoint
base analysi believ roxadustat offer azn investor posit risk/reward
believ safeti result support
broad eu approv base mace non-inferior dd ndd patient group
us approv dd current market esa
chanc approv ndd improv convict requir present
full dataset togeth commun fda mace analysi guidanc ndd
page analyst certif import disclosur
non-dialysi depend ndd indic concern
clinic meaning differ vs placebo
overreact base primarili lack clear commun
fgen/azn regard hazard ratio safeti analysi
base compani commun clearli differ
aranesp treat omontyss pearl studi sinc similar
result would disclos investor
ndd approv mace compon like
consist particularli sinc roxa achiev non-inferior
us dd china alon justifi roxa sale
leav ndd approv compel upsid option
ndd mean classic fail studi languag
without fda agreement non-inferior margin
statist analysi plan sap possibl guess
likelihood approv
fgen/azn comparison placebo poorli control
confound dropout/censor put odd
dd may approv there way take
share especi compet bundl epo
base detail analysi fgen earn call along sever follow commun azn
analysi fda treatment anemia product non-inferior margin across multipl class drug esa well
agenc guidanc evalu cv risk type diabet believ roxadustat mace result suggest
full us approv roxadustat treatment anemia dialysi depend dd patient
like late
chanc approv ndd assum hazard ratio data set consist
interpret fgen/azn feedback
narrow label includ ckd stage egfr would surpris us
page analyst certif import disclosur
page analyst certif import disclosur
anemia ckd seriou condit high unmet need
anemia chronic kidney diseas ckd
seriou medic condit patient insuffici red blood cell low level hemoglobin
associ increas risk hospit cardiovascular complic need blood transfus exacerb
seriou medic condit death
commonli caus diabet hypertens
ckd affect million peopl world-wide anemia significantli increas healthcar cost patient
stage ckd primarili defin measur filtrat function kidney gfr
ckd
usag
esa dd
ndd estim pool
time dd pool
page analyst certif import disclosur
brief histori esa cv safeti risk fda label updat
reimburs chang ckd prompt declin epo usag
fda approv epoetin alfa tx
anemia ckd
epoetin help elev
esa given intraven
subcutan iv dose
studi prove esa major
fda mandat black
warn esa packag insert
led declin esa ndd
launch esa procrit
biosimilar retacrit
launch procrit
esa
mippa bundl introduc cover
cost esa iv iron dose
fda chang label ad esa
use ckd patient hb level g/dl
average dose esa also declin compar
due toxic high dose esa
launch
roxadustat
china hif-phi
ndd non-dialysi depend red blood cell esa erythropoiesi stimul agent cv cardiovascular death myocardi infract stroke mippa medicar prescript drug improv
modern act hif-phi hypoxia-induc factor prolyl hydroxylas inhibitor
page analyst certif import disclosur
global market ndd use restrict drove sustain declin esa sale
trend revers reli novel hif-phi class
retacrit
launch
epogen esa
epogen esa
page analyst certif import disclosur
roxadustat first market oral iv novel hif epo
roxadustat hypoxia-induc factor prolyl hydroxylas inhibitor hif-phi current partner
astrazeneca azn us/row china
approv dialysi
depend china
china
nrdl expect dd
astella submit
roxadustat ema
overcom suppress effect inflamm
erythropoietin level within near physiolog rang
small statist superior esa shown
hemoglobin chang baselin well reduct
risk blood cell transfus
azn/fgen submit
roxadustat nda fda
ndd dd
astella submit j-
nda roxadustat
dialysi
nda submiss
page analyst certif import disclosur
us anemia market forecast minim esa use ndd epo biosimilar
price pressur novel hif-phi class anemia market recoveri
retacrit
launch
epogen esa
epogen esa
page analyst certif import disclosur
ndd crux azn us opportun roxadustat
strong efficaci data trial
mace event hr composit
conveni oral drug expand util
first mover hif-phi class advantag
alreadi approv launch china
dropout rate henc criteria evalu
ndd label expans us particularli ckd
margin better hb efficaci
better expect secondari end point
slow declin egfr improv qualiti life
md phase chemo-induc
histori entrench dialysi market
impact price uptak
page analyst certif import disclosur
estim roxadustat china potenti
first countri approv novel hif-phi molecul
nda approv nmpa dialysis-depend patient decemb
nda approv non-dialysi depend anticip
underserv grow emerg patient popul growth rate yoy
china dialysis-depend doubl past year
diabet hypertens common caus ckd rate grow china
increas diabet hypertens preval result increas number patient ckd
futur
ndd-ckd elig patient popul estim
inclus nrdl list lead expans reimburs
roxadustat inclus nation reimburs drug list nrdl dialysi depend patient
expect
anemia myelodysplast syndrom md difficult treat popul studi
page analyst certif import disclosur
page analyst certif import disclosur
analysi across major subgroup ndd id dd
stabl dialysi vs epoetin alfa
japan phase ckd-ndd studi snda ndd
non-dialysi vs darbepoetin eu
page analyst certif import disclosur
roxadustat paradox ema approv like azn/fgen us cv
safeti situat murkybut believ better mani think
pool group safeti analysi
incid dialysi id newli treat
esa subgroup dd
compar epoetin alfa
unknown mace
pre-agr fda non-inferior margin nim across group
non-inferior placebo
hazard ratio
superior epoetin alfa
upper bound ci less
hazard ratio way
posit mace
pre-agre ema specifi nim upper bound ci mace pre-agre nim
support efficaci safeti
chang egfr chang renal
fda ema assess risk/benefit profil roxadustat
declin efgr roxadustat vs
slower egfr declin
qualiti life
pool group subgroup specifi
improv qualiti life
endpoint week
roxadustat efficaci compar epoetin alfa affect inflamm statu
intent treat analys
mace mace mace cv time mace time mace case result analysi ratio
standard non-inferior comparison
mace major advers cardiac event time first occurr death myocardi infarct stroke mace mace hospit heart failur unstabl angina
page analyst certif import disclosur
page analyst certif import disclosur
ndd approv prospect histori suggest mace
compon need consist similar placebo
peginesatid omonti
anemia ckd
non- dialysi
hr predict reduct
risk
trial statu cv
anemia ckd
non-dialysi
death cv
fatal non-fat
fail ub stroke
high vs hemoglobin
anemia ckd
non-dialysi
anemia ckd
non-dialysi
fail ub
insight non-dialysi independ ndd pool safeti result roxadustat
roxadustat pool safeti result safeti signal similar treat/pearl believ azn/fgen would disclos immedi
omonti pearl studi trial fail due elev mace risk ub mace event hr
aranesp treat studi trial suggest increas risk stroke despit non-inferior composit end point
unconfirm believ like ndd patient compon mace hr near
impact dropout rate ndd group confirm becam appar fgen/azn
commun fda unclear analysi appropri and/or conserv exposure-adjust analysi azn
state us fda evalu total data analys would avail fda evalu
page analyst certif import disclosur
